Skip to main content
. 2024 Oct 25;25(21):11458. doi: 10.3390/ijms252111458

Figure 2.

Figure 2

SGLT2is’ beneficial effects on different HF scenarios. ATTR-CM: Transthyretin amyloid cardiomyopathy; CKD: chronic kidney disease; HF: heart failure; LVEDV: left ventricular end-diastolic volume; LVESV: left ventricular end-systolic volume; NT-proBNP: N-terminal pro-b-type natriuretic peptide; SGLT2i: sodium-glucose cotransporter 2 inhibitor.